Does Transcatheter Aortic-Valve Implantation (TAVI) reduce death from any cause in patients with severe aortic stenosis who cannot undergo surgery?
TAVI significantly reduces mortality and hospitalizations in patients with severe aortic stenosis who are ineligible for surgery, though it increases the risk of major strokes and vascular events.
In patients with severe aortic stenosis who were not suitable candidates for surgery, TAVI, as compared with standard therapy, significantly reduced the rates of death from any cause, the composite end point of death from any cause or repeat hospitalization, and cardiac symptoms, despite the higher incidence of major strokes and major vascular events. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).
Leon et al. (2010) studied this question.